TCGA-56-A4ZJ-01A-11R-A262-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.630
- ANGIOGENESIS+0.580
- COAGULATION+0.530
- APICAL_JUNCTION+0.470
- MYOGENESIS+0.460
- HEDGEHOG_SIGNALING+0.420
- IL6_JAK_STAT3_SIGNALING+0.420
- APICAL_SURFACE+0.410
- INFLAMMATORY_RESPONSE+0.370
- KRAS_SIGNALING_UP+0.350
Top 10 suppressed
- MYC_TARGETS_V2-0.690
- E2F_TARGETS-0.640
- MYC_TARGETS_V1-0.620
- G2M_CHECKPOINT-0.570
- OXIDATIVE_PHOSPHORYLATION-0.430
- MTORC1_SIGNALING-0.420
- DNA_REPAIR-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.390
- INTERFERON_ALPHA_RESPONSE-0.280
- SPERMATOGENESIS-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AC-A23G-01A-11R-A213-07 | — | A | 0.959 |
| 2 | TCGA-OL-A6VQ-01A-12R-A41B-07 | — | A | 0.950 |
| 3 | TCGA-75-7030-01A-11R-1949-07 | — | cohortA1 | 0.944 |
| 4 | SRR35579845 | — | A | 0.939 |
| 5 | TCGA-E2-A1IJ-01A-11R-A144-07 | — | A | 0.937 |
| 6 | TCGA-A2-A0CZ-01A-11R-A034-07 | — | A | 0.937 |
| 7 | TCGA-LL-A440-01A-11R-A24H-07 | — | A | 0.931 |
| 8 | SRR1498861 | GTEX | — | 0.929 |
| 9 | TCGA-BH-A0DV-01A-21R-A12P-07 | — | A | 0.927 |
| 10 | TCGA-E2-A153-01A-12R-A12D-07 | — | A | 0.926 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.630 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.580 | Remibrutinib | — uncovered |
| COAGULATION | 0.530 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.470 | Inavolisib | — uncovered |
| MYOGENESIS | 0.460 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.420 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.410 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| COMPLEMENT | 0.340 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.270 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.270 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |